WEBULL
News
PTHS
25.71
-2.98%
-0.79
*Pelthos Therapeutics: Einhorn Increases Board to Eight Directors >PTHS
Dow Jones · 3d ago
*Pelthos Therapeutics Names Andrew J. Einhorn to Board
Dow Jones · 3d ago
Press Release: Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
Dow Jones · 3d ago
Pelthos Therapeutics Adds Veteran Finance Executive to Board
TipRanks · 3d ago
Alliance Global Partners Sticks to Its Buy Rating for Pelthos Therapeutics (PTHS)
TipRanks · 4d ago
Weekly Report: what happened at PTHS last week (1215-1219)?
Weekly Report · 4d ago
Pelthos Therapeutics Concludes 2025 Annual Stockholder Meeting
TipRanks · 12/17 21:54
Analysts Offer Insights on Healthcare Companies: Novan (NOVN), Pelthos Therapeutics (PTHS) and Scholar Rock Holding (SRRK)
TipRanks · 12/15 12:30
Weekly Report: what happened at PTHS last week (1208-1212)?
Weekly Report · 12/15 10:37
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (PTHS), Insmed (INSM) and IDEAYA Biosciences (IDYA)
TipRanks · 12/08 13:30
Weekly Report: what happened at PTHS last week (1201-1205)?
Weekly Report · 12/08 10:36
Analysts Are Bullish on Top Healthcare Stocks: Pelthos Therapeutics (PTHS), Praxis Precision Medicines (PRAX)
TipRanks · 12/05 14:10
Analysts Are Bullish on These Healthcare Stocks: Pelthos Therapeutics (PTHS), Praxis Precision Medicines (PRAX)
TipRanks · 12/05 14:00
Pelthos signs benefit manager agreement expanding patient access to ZELSUVMI
TipRanks · 12/04 12:05
Pelthos Signs First Big Deal to Expand Access to Its At-Home Treatment for Molluscum
Benzinga · 12/04 12:03
Pelthos Therapeutics Price Target Announced at $50.00/Share by Lake Street
Dow Jones · 12/03 19:13
Lake Street Initiates Coverage On Pelthos Therapeutics with Buy Rating, Announces Price Target of $50
Benzinga · 12/03 19:03
Lake Street starts Pelthos with a Buy on ‘category-leader potential’
TipRanks · 12/03 14:05
This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Benzinga · 12/03 14:01
Pelthos Therapeutics initiated with a Buy at Lake Street
TipRanks · 12/03 13:15
More
Webull provides a variety of real-time PTHS stock news. You can receive the latest news about Pelthos Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About PTHS
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi (ozenoxacin) Cream, 1%, which is a non-fluorinated quinolone antimicrobial indicated for the topical treatment of impetigo. The Company is also evaluating the path forward for its existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.